FITC-Labeled Human respiratory syncytial virus A (strain A2) Pre-F0 Protein, His Tag

Customer Reviews
Cat. No. / Size
Price
Qty
RSF-V52H3-50ug
$465.00
RSF-V52H3-500ug (250ug X 2)
$2885.00
ETA of in-stock products:2 business days

Product Details

  • Synonyms

    Prefusion glycoprotein F0/pre-F protein (RSV)

  • Source

    FITC-Labeled Human respiratory syncytial virus A (strain A2) Pre-F0, His Tag (RSF-V52H3) is expressed from human 293 cells (HEK293). It contains AA Gln 26- Leu 513 (Accession # P03420). It is the FITC labeled form of HRSV (A) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7).

  • Molecular Characterization

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 56.1 kDa. The protein migrates as 60-65 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Conjugate

    FITC

    Excitation source: 488 nm spectral line, argon-ion laser

    Excitation Wavelength: 488 nm

    Emission Wavelength: 535 nm

  • Labeling

    The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with FITC using standard chemical labeling method. The residual FITC is removed by molecular sieve treatment during purification process.

  • Protein Ratio

    The FITC to protein molar ratio is 1.0-2.0.

  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please protect from light and avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • SDS-PAGE

    Prefusion glycoprotein F0/pre-F protein (RSV) SDS-PAGE

    FITC-Labeled Human respiratory syncytial virus A (strain A2) Pre-F0, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

  • Bioactivity-ELISA

     Prefusion glycoprotein F0/pre-F protein (RSV) ELISA

    Immobilized Anti-Fusion glycoprotein F0 Antibody, Human IgG1 (D25) at 2 μg/mL (100 μL/well) can bind FITC-Labeled Human respiratory syncytial virus A (strain A2) Pre-F0, His Tag (Cat. No. RSF-V52H3) with a linear range of 0.02-0.625 μg/mL (QC tested).

    Protocol

Customer Reviews
Writing Reviews

FAQ

  • Product

    What do “pre” and “post” refer to in the names of viral proteins?

    In virology, “pre” refers to the conformation of a viral surface glycoprotein before fusion with the host cell membrane, while “post” refers to the conformation after membrane fusion and entry into the host cell. Both are naturally occurring states in the viral life cycle. Because the “pre” conformation represents a critical stage before viral entry, antibodies designed against this state often exhibit stronger neutralizing activity and are therefore more effective in preventing infection.

Background

Human respiratory syncytial virus (HRSV) is the most common etiological agent of acute lower respiratory tract disease in infants and can cause repeated infections throughout life. The RSV fusion glycoprotein (RSV F) is the principal target of RSV neutralizing antibodies in human sera. The RSV F is a type I viral fusion protein synthesized as inactive, single-chain polypeptides that assemble into trimers. RSV F fuses the viral and host cell membranes by irreversible protein refolding from the labile prefusion conformation to the stable post-fusion conformation. Both states exhibit epitopes targeted by neutralizing antibodies, and post-fusion RSV F is being developed as a vaccine candidate.

Recent Advances

 
Contact Us
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • FAQ
  • Background
Contact Us

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8